Clinical Trial Update: Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Rituximab-HCVAD alternating with Rituximab-Methotrexate-Cytarabine vs Rituximab-CHOP in newly diagnosed high-risk aggressive B-cell non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab-CHOP (Rituximab-CHOP)
• Rituximab-HCVAD (Rituximab-HCVAD)
• Rituximab-Methotrexate-Cytarabine (Rituximab, Methotrexate, Cytarabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-06-02